OKLAHOMA CITY, June 30, 2020 /PRNewswire/ — Cortado Ventures is pleased to announce the initial close of their fund was completed in four weeks, with significant progress made toward the fund’s overall target raise. Reaching this milestone in less than a month since launching is critical in fulfilling their mission to support high growth disruptive startups.
- Cortado Ventures Doubleshot Newsletter: October 2022
- Cortado Ventures Doubleshot Newsletter: September 2022
- Moat Biotechnology Forms To Develop Novel Mucosal Vaccines for Covid-19 and Beyond: Announces Initial Funding Round and Promising Phase I trial results for Intranasal Covid-19 Vaccine
- Cortado Ventures Doubleshot Newsletter: August 2022
- Cortado Ventures Starting Second Close at $40M for Fund II